Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 244

Similar articles for PubMed (Select 15262269)

1.
2.

The neurotoxin 2'-NH2-MPTP degenerates serotonin axons and evokes increases in hippocampal BDNF.

Luellen BA, Szapacs ME, Materese CK, Andrews AM.

Neuropharmacology. 2006 Mar;50(3):297-308. Epub 2005 Nov 9.

PMID:
16288930
3.

Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice.

Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T.

J Neuropathol Exp Neurol. 2004 May;63(5):418-28.

PMID:
15198121
6.

Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway.

Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, Mufson EJ.

Exp Neurol. 2001 Aug;170(2):227-43.

PMID:
11476589
7.

Alteration of cortical EEG in mice carrying mutated human APP transgene.

Wang J, Ikonen S, Gurevicius K, van Groen T, Tanila H.

Brain Res. 2002 Jul 12;943(2):181-90.

PMID:
12101040
8.

Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice.

Luellen BA, Bianco LE, Schneider LM, Andrews AM.

Genes Brain Behav. 2007 Jul;6(5):482-90. Epub 2006 Dec 6.

PMID:
17156118
9.

Neuronal and astroglial responses to the serotonin and norepinephrine neurotoxin: 1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine.

Luellen BA, Miller DB, Chisnell AC, Murphy DL, O'Callaghan JP, Andrews AM.

J Pharmacol Exp Ther. 2003 Dec;307(3):923-31. Epub 2003 Oct 15.

10.

APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1.

Jankowsky JL, Slunt HH, Gonzales V, Jenkins NA, Copeland NG, Borchelt DR.

Neurobiol Aging. 2004 Aug;25(7):885-92.

PMID:
15212842
11.

Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.

Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R, Gardier AM.

Neuropharmacology. 2008 Nov;55(6):1006-14. doi: 10.1016/j.neuropharm.2008.08.001. Epub 2008 Aug 12. Review.

PMID:
18761360
12.
13.

Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice.

Puoliväli J, Wang J, Heikkinen T, Heikkilä M, Tapiola T, van Groen T, Tanila H.

Neurobiol Dis. 2002 Apr;9(3):339-47.

PMID:
11950278
14.

Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits.

Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, Heneka MT.

Neurochem Int. 2010 Nov;57(4):375-82. doi: 10.1016/j.neuint.2010.02.001. Epub 2010 Feb 6.

PMID:
20144675
15.
16.
18.

GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.

Tian J, Shi J, Zhang L, Yin J, Hu Q, Xu Y, Sheng S, Wang P, Ren Y, Wang R, Wang Y.

Curr Alzheimer Res. 2009 Apr;6(2):118-31.

PMID:
19355846
19.

Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice.

Wang J, Tanila H, Puoliväli J, Kadish I, van Groen T.

Neurobiol Dis. 2003 Dec;14(3):318-27. Erratum in: Neurobiol Dis. 2004 Jun;16(1):following 289.

PMID:
14678749
20.

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K, Duff K.

Nat Med. 1998 Jan;4(1):97-100.

PMID:
9427614
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk